Buysschaert M - Search Results

1

Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.

Kitoga M, Pasquet A, Preumont V, Kefer J, Hermans MP, Vanoverschelde JL, Buysschaert M. Kitoga M, et al. Among authors: buysschaert m. Diabetes Metab. 2008 Feb;34(1):62-7. doi: 10.1016/j.diabet.2007.09.002. Diabetes Metab. 2008. PMID: 18069029

2

Erectile dysfunction and lower androgenicity in type 1 diabetic patients.

Alexopoulou O, Jamart J, Maiter D, Hermans MP, De Hertogh R, De Nayer P, Buysschaert M. Alexopoulou O, et al. Among authors: buysschaert m. Diabetes Metab. 2001 Jun;27(3):329-36. Diabetes Metab. 2001. PMID: 11431598

3

Micro- and macrovascular complications and hyperhomocysteinaemia in type 1 diabetic patients.

Buysschaert M, Jamart J, Dramais AS, Wallemacq P, Hermans MP. Buysschaert M, et al. Diabetes Metab. 2001 Dec;27(6):655-9. Diabetes Metab. 2001. PMID: 11852373

4

Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous mutations for haemochromatosis.

Van Lerberghe S, Hermans MP, Dahan K, Buysschaert M. Van Lerberghe S, et al. Among authors: buysschaert m. Diabetes Metab. 2002 Feb;28(1):33-8. Diabetes Metab. 2002. PMID: 11938026

5

Comparative performance of serum cystatin-c versus serum creatinine in diabetic subjects.

Buysschaert M, Joudi I, Wallemacq P, Hermans MP. Buysschaert M, et al. Diabetes Metab. 2003 Sep;29(4 Pt 1):377-83. doi: 10.1016/s1262-3636(07)70048-4. Diabetes Metab. 2003. PMID: 14526265

6

C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemia.

Buysschaert M, Gala JL, Bessomo A, Hermans MP. Buysschaert M, et al. Diabetes Metab. 2004 Sep;30(4):349-54. doi: 10.1016/s1262-3636(07)70127-1. Diabetes Metab. 2004. PMID: 15525878

7

The treat-to-target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients.

Buysschaert M, Hermans MP. Buysschaert M, et al. Acta Clin Belg. 2005 Mar-Apr;60(2):79-85. doi: 10.1179/acb.2005.015. Acta Clin Belg. 2005. PMID: 16082993

8

Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.

Preumont V, Hermans MP, Brichard S, Buysschaert M. Preumont V, et al. Among authors: buysschaert m. Diabetes Metab. 2010 Sep;36(4):293-8. doi: 10.1016/j.diabet.2010.02.001. Epub 2010 May 5. Diabetes Metab. 2010. PMID: 20447851

9

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.

Buysschaert M, Preumont V, Oriot PR, Paris I, Ponchon M, Scarnière D, Selvais P; UCL Study Group for Exenatide. Buysschaert M, et al. Diabetes Metab. 2010 Nov;36(5):381-8. doi: 10.1016/j.diabet.2010.03.009. Epub 2010 Jul 2. Diabetes Metab. 2010. PMID: 20598606

10

Improvement of psoriasis during exenatide treatment in a patient with diabetes.

Buysschaert M, Tennstedt D, Preumont V. Buysschaert M, et al. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004. Epub 2012 Jan 9. Diabetes Metab. 2012. PMID: 22227407

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters